参考文献:
1.《2020中国癌症患者生存质量白皮书》
2.David L. Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012 May;11(5):401-19.
3.Stopeck AT, Lipton A, Body JJ,Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acidfor the treatment of bone metastases in patients with advanced breast cancer: arandomized, double-blind study. J Clin Oncol 2010 Dec 10;28(35):5132-9.
4.Henry DH, Costa L, GoldwasserF, et al. Randomized, double-blind study of denosumab versus zoledronic acid inthe treatment of bone metastases in patients with advanced cancer (excludingbreast and prostate cancer) or multiple myeloma. J Clin Oncol.2011;29(9):1125‐1132. doi:10.1200/JCO.2010.31.3304.
5.Fizazi K, Carducci M, Smith M,et al. Denosumab versus zoledronic acid for treatment of bone metastases in menwith castration-resistant prostate cancer: a randomised, double-blind study.Lancet. 2011;377(9768):813‐822. doi:10.1016/S0140-6736(10)62344-6.